East Norriton, Pennsylvania-based regenerative medicine company Tengion Inc. announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission relating to the proposed initial public offering of up to $40.25 million shares of its common stock.
The company stated that the number of shares to be offered and the price range of the offering have not yet been determined. The company plans to list its common stock in the Nasdaq Global Market under the proposed trading symbol "TNGN"
According to the filing, Oak Investment Partners XI, Limited Partnership beneficially own 19.6%, HealthCap Venture Capital own 14.3%, Johnson & Johnson Development Corp. own 12.5%, Brookside Capital Partners Fund, L.P. hold 8.6%, Bain Capital Venture Entities hold 8.5%, Quaker BioVentures own 8.3%, and L Capital Partners SBIC, L.P. own 6.4% of shares, prior to this initial offering.
Piper Jaffray & Co. is acting as sole book-running manager for this offering and as representative of the underwriters.
For the nine months ended September 30, 2009, the company reported net loss attributable to common stockholders of $33.67 million, versus a loss attributable to common stockholders of $39.92 million in the comparable period last year.
For comments and feedback: editorial@rttnews.com